ATE458735T1 - Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs - Google Patents

Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Info

Publication number
ATE458735T1
ATE458735T1 AT04776639T AT04776639T ATE458735T1 AT E458735 T1 ATE458735 T1 AT E458735T1 AT 04776639 T AT04776639 T AT 04776639T AT 04776639 T AT04776639 T AT 04776639T AT E458735 T1 ATE458735 T1 AT E458735T1
Authority
AT
Austria
Prior art keywords
pyridino
compounds
pyrimidine
cancer agent
alone
Prior art date
Application number
AT04776639T
Other languages
English (en)
Inventor
Weibo Wang
Ryan N Constantine
Liana M Lagniton
Sabina Pecchi
Matthew T Burger
Manoj C Desai
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE458735T1 publication Critical patent/ATE458735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04776639T 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs ATE458735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48018003P 2003-06-20 2003-06-20
PCT/US2004/019158 WO2004113335A2 (en) 2003-06-20 2004-06-17 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

Publications (1)

Publication Number Publication Date
ATE458735T1 true ATE458735T1 (de) 2010-03-15

Family

ID=33539266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776639T ATE458735T1 (de) 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Country Status (15)

Country Link
US (1) US7326711B2 (de)
EP (1) EP1636225B1 (de)
JP (1) JP2007520435A (de)
KR (1) KR20060069356A (de)
CN (1) CN1809563A (de)
AT (1) ATE458735T1 (de)
AU (1) AU2004249730A1 (de)
CA (1) CA2528771A1 (de)
DE (1) DE602004025698D1 (de)
ES (1) ES2339862T3 (de)
IL (1) IL172192A0 (de)
MX (1) MXPA05013142A (de)
PT (1) PT1636225E (de)
TW (1) TW200503719A (de)
WO (1) WO2004113335A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156304A0 (en) * 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2005082343A2 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
RU2006138864A (ru) * 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
RU2007106552A (ru) * 2004-07-22 2008-08-27 Астразенека Аб (Se) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
UA89201C2 (ru) * 2004-08-18 2010-01-11 Астразенека Аб Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP1778669A2 (de) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
EP1812439B2 (de) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
KR20080006614A (ko) * 2005-04-14 2008-01-16 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR20090097210A (ko) 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
RS53494B9 (sr) 2009-06-29 2020-11-30 Incyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
BR122019020716B1 (pt) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
EP3406252B1 (de) * 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Verbindungen zur behandlung von spinaler muskelatrophie
CN104302181B (zh) 2012-03-01 2017-09-15 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3262046B1 (de) 2015-02-27 2020-11-04 Incyte Corporation Pi3k-hemmer-salze und verfahren zu ihrer herstellung
JP6847851B2 (ja) * 2015-04-15 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016184832A1 (en) * 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3386511B2 (de) 2015-12-10 2024-03-20 PTC Therapeutics, Inc. Verfahren zur behandlung von morbus huntington
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3638318A4 (de) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. Verfahren zur modulation von rna-splicing
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN108191860B (zh) * 2018-02-12 2019-12-10 中国医科大学 一种HIF-2α小分子抑制剂及其用途
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
EP3814360B8 (de) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl verbindungen zur behandlung von morbus huntington
SG11202012674PA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (en) 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
GB2307177A (en) 1995-11-15 1997-05-21 Agrevo Uk Ltd Fungicidal pyridopyrimidines
NZ518480A (en) 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
CA2440219A1 (en) * 2001-02-21 2002-10-17 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
EP1444209A4 (de) * 2001-11-07 2005-02-16 Merck & Co Inc Inhibitoren mitotischer kinesine
EP1481077B1 (de) * 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotische kinesin-hemmer
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
EP1594849A4 (de) * 2003-01-17 2007-07-04 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren

Also Published As

Publication number Publication date
WO2004113335A3 (en) 2005-03-24
EP1636225A2 (de) 2006-03-22
CN1809563A (zh) 2006-07-26
US20050085490A1 (en) 2005-04-21
JP2007520435A (ja) 2007-07-26
ES2339862T3 (es) 2010-05-26
DE602004025698D1 (de) 2010-04-08
WO2004113335A2 (en) 2004-12-29
MXPA05013142A (es) 2006-03-17
EP1636225B1 (de) 2010-02-24
KR20060069356A (ko) 2006-06-21
AU2004249730A1 (en) 2004-12-29
US7326711B2 (en) 2008-02-05
TW200503719A (en) 2005-02-01
PT1636225E (pt) 2010-05-03
IL172192A0 (en) 2006-04-10
CA2528771A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
ATE458735T1 (de) Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
WO2004006859A3 (en) Platinum compound
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
FR13C0062I1 (de)
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
WO2009143156A3 (en) Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
HRP20130459T1 (en) Topical co-enzyme q10 formulations and methods of use
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2002028860A3 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
PH12012502122A1 (en) Imidazo[1,2-a]pyridine derivative
IL184131A0 (en) Pyrido (3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties